Combining nicotinamide with a first-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) in patients with stage IV lung cancer harboring an EGFR mutation could potentially improve patients' progression-free and overall survival, with significant survival benefits for female patients and those who have never smoked (NCT02416739) 304. Here, EGFR is linked to lung carcinoma.